|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2008-6-5
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18525047,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18768954,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18777611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18777612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18777613,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18838970,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18838983,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18844771,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18959827,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-18959834,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-19291865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-19424672,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18525041-19476576
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2008 Massachusetts Medical Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
5
|
|
pubmed:volume |
358
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2433-46
|
|
pubmed:dateRevised |
2009-8-14
|
|
pubmed:meshHeading |
pubmed-meshheading:18525041-Adolescent,
pubmed-meshheading:18525041-Adult,
pubmed-meshheading:18525041-Aged,
pubmed-meshheading:18525041-Aged, 80 and over,
pubmed-meshheading:18525041-Albuminuria,
pubmed-meshheading:18525041-Amides,
pubmed-meshheading:18525041-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:18525041-Antihypertensive Agents,
pubmed-meshheading:18525041-Creatinine,
pubmed-meshheading:18525041-Diabetes Mellitus, Type 2,
pubmed-meshheading:18525041-Diabetic Nephropathies,
pubmed-meshheading:18525041-Double-Blind Method,
pubmed-meshheading:18525041-Drug Therapy, Combination,
pubmed-meshheading:18525041-Female,
pubmed-meshheading:18525041-Fumarates,
pubmed-meshheading:18525041-Humans,
pubmed-meshheading:18525041-Hypertension,
pubmed-meshheading:18525041-Losartan,
pubmed-meshheading:18525041-Male,
pubmed-meshheading:18525041-Middle Aged,
pubmed-meshheading:18525041-Multivariate Analysis,
pubmed-meshheading:18525041-Proteinuria,
pubmed-meshheading:18525041-Renin
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
|
|
pubmed:affiliation |
Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark. hhparving@dadlnet.dk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
